IBT offentliggör utfall i företrädesemissionen
04 juil. 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
Ytterligare Infant Bacterial Therapeutics produkt beviljas “orphan drug” status av FDA
03 juil. 2023 10h39 HE
|
Infant Bacterial Therapeutics AB
FDA har beviljat särläkemedelsstatus för IBT:s produkt IBP-1016 för gastroschisis. Barn som drabbas av gastroschisis har ökade risker av tillväxthämning, sepsis och NEC vilket i sin tur...
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
03 juil. 2023 10h39 HE
|
Infant Bacterial Therapeutics AB
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to...
Rare Diseases Market Report 2023-2033: Home-based Care Anticipated to Offer Lucrative Growth Prospects
26 juin 2023 04h18 HE
|
Research and Markets
Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The "Rare Diseases Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the Rare Diseases...
ADR Ratio Change
22 juin 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
Futilitetsanalysen för IBTs Connection Study positiv
21 juin 2023 11h20 HE
|
Infant Bacterial Therapeutics AB
“IBT har tidigare idag meddelat att Data Monitoring Committee (DMC) utfört den planerade säkerhetsgenomgången av studiedata av 1403 för tidigt födda barn. Vi nu även erhållit resultat från den...
The futility analysis for IBT’s Connection Study positive
21 juin 2023 11h20 HE
|
Infant Bacterial Therapeutics AB
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies. We have now also received results from the...
IBT fortsätter rekrytera för tidigt födda barn till The Connection Study efter planerad säkerhetsanalys
21 juin 2023 02h55 HE
|
Infant Bacterial Therapeutics AB
I enlighet med studieprotokollet har den oberoende Data Monitoring Committee (DMC) utfört den sista planerade säkerhetsanalysen av Infant Bacterial Therapeutics AB (IBT) läkemedelskandidat IBP-9414....
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
21 juin 2023 02h55 HE
|
Infant Bacterial Therapeutics AB
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of Infant Bacterial Therapeutics AB (IBT) drug candidate...
Appeal of Delisting Determination
20 juin 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...